CD274 and hepatocellular carcinoma: Combining PD-1/PD-L1 inhibitors with tyrosine kinase inhibitors (TKIs) has been shown to stabilize the immune contexture in HBV-positive HCC, creating a more favorable TME for immunotherapy (31).